P1.27-10 NEOIPOWER: Icotinib plus Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFR-mutant Lung Adenocarcinoma

Neoadjuvant treatment has demonstrated efficacy in several tumors and is increasingly used for the treatment of early-stage disease with the potential of tumor downstaging to enhance complete surgical resection and to improve clinical outcomes. EGFR tyrosine kinase inhibitors (EGFR-TKIs) have shown activity as monotherapy in the neoadjuvant setting, however, data on the combination of neoadjuvant EGFR-TKIs are limited. This study aimed to evaluate the safety and efficacy of neoadjuvant icotinib plus chemotherapy for stage II-IIIB EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC).